The Potential Of Artocarpus Lacucha Linn In Alleviating Depressant & Anxiety Disorder Effects: A Review
Abstract
Artocarpus lacucha Linn is a traditional herbal medicine used for different diseases and they have a good anti-oxidant nature to help treat neuroinflammation and protect the potential of anti-depressants, anti-anxiety. Commonly known as Monkey Jack or Monkey Fruit, is a tropical fruit-bearing tree found in Southeast Asia. This review article aims to explore the potential mechanisms and evidence supporting the role of Artocarpus lacucha in combating antidepressant and antianxiety effects, and increase the GABA, GABAA&B levels and improving mental health, shedding light on its pharmacological properties, and highlighting avenues for further research. The findings indicate that while mitochondrial protection was difficult to achieve, both of the substances studied Artocarpus lacucha Linn —improved cell survival, particularly in relation to ROS and lipid peroxidation. Because of the effectiveness of the redox-sensitive expression of antioxidant enzymes and its pharmacokinetic properties, oral Artocarpus lacucha Linn may offer useful protection against acute neurodegenerative diseases.
References
Marbin D, Gutwinski S, Schreiter S, Heinz A. Perspectives in poverty and mental health. Front Public Heal. 2022;10:975482.
Brauer R, Alfageh B, Blais JE, Chan EW, Chui CSL, Hayes JF, et al. Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study. The Lancet Psychiatry. 2021;8(12):1071–82.
Meghrajani VR, Marathe M, Sharma R, Potdukhe A, Wanjari MB, Taksande AB, et al. A Comprehensive Analysis of Mental Health Problems in India and the Role of Mental Asylums. Cureus. 2023;15(7).
Zhang X, Hu X, Zhao Y, Lu CY, Nie X, Shi L. Trends in the utilization of psychotropic medications in China from 2018 to 2021. Front Pharmacol. 2022;13:967826.
Tiger M, Wesselhoeft R, Karlsson P, Handal M, Bliddal M, Cesta CE, et al. Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia. J Affect Disord. 2023;323:292–8.
Estrela M, Herdeiro MT, Ferreira PL, Roque F. The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: focusing on mental health care in Portugal and prescribing in older patients. Int J Environ Res Public Health. 2020;17(22):8612.
Woo YS, Park JE, Kim DH, Sohn I, Hwang TY, Park YM, et al. Blonanserin augmentation of atypical antipsychotics in patients with schizophrenia-who benefits from blonanserin augmentation?: an open-label, prospective, multicenter study. Psychiatry Investig. 2016;13(4):458.
Kim J, Kim TE, Lee SH, Koo JW. The Role of Glutamate Underlying Treatment-resistant Depression. Clin Psychopharmacol Neurosci. 2023;21(3):429.
Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23(1):1.
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014;29(4):185–96.
Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety/sedative drug use. N Engl J Med. 1974;290(14):769–74.
Horih SI. Basic neurochemistry: molecular, cellular, and medical aspects. Neurology. 1989;39(3):460.
Purves D, Augustine G, Fitzpatrick D, Katz L, LaMantia A, McNamara J, et al. Neuroscience 2nd edition. sunderland (ma) sinauer associates. Types Eye Movements Their Funct. 2001;
Chandel SS. Pharmacological models to appraisement of antianxiety activity in experimental animals. Int J Green Pharm. 2018;12(03).
Beck AT, Alford BA. Depression: Causes and treatment. University of Pennsylvania Press; 2009.
Goodwin GM. The overlap between anxiety, depression, and obsessive-compulsive disorder. Dialogues Clin Neurosci. 2015;17(3):249–60.
Bakker A, Van Balkom A, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta‐analysis. Acta Psychiatr Scand. 2002;106(3):163–7.
He H, Xiang Y, Gao F, Bai L, Gao F, Fan Y, et al. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res. 2019;118:21–30.
Curtiss J, Andrews L, Davis M, Smits J, Hofmann SG. A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators. Expert Opin Pharmacother. 2017;18(3):243–51.
Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23:427–52.
Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol. 2007;27(3):263–72.
Balon R, Starcevic V. Role of benzodiazepines in anxiety disorders. Anxiety Disord Rethink Underst Recent Discov. 2020;367–88.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Jama. 2011;306(12):1359–69.
Depping AM, Komossa K, Kissling W, Leucht S. Second‐generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12).
Steenen SA, Van Wijk AJ, Van Der Heijden GJMG, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128–39.
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;(12).
Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha AABC, Kapczinski F, Silva de Lima M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 1996;2015(6).
Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013;12(9):667–87.
Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis. Asian J Psychiatr. 2017;26:115–22.
Schneier FR, Moskow DM, Choo T, Galfalvy H, Campeas R, Sanchez‐Lacay A. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depress Anxiety. 2017;34(12):1085–95.
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–77.
Yee A, Ng CG, Seng LH. Vortioxetine treatment for anxiety disorder: a meta-analysis study. Curr Drug Targets. 2018;19(12):1412–23.
Shah A, Northcutt J. An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Ann Gen Psychiatry. 2018;17:1–7.
Bansal Y, Bhandari R, Kaur S, Kaur J, Singh R, Kuhad A. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties. Drugs of Today (Barcelona, Spain: 1998). 2019;55(7):423–37.
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front psychiatry. 2020;11:595584.
Nishitsuji K, To H, Murakami Y, Kodama K, Kobayashi D, Yamada T, et al. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clin Drug Investig. 2004;24:121–6.
Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons Jr EC, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008;28(2):235–9.
Staroń J, Bugno R, Hogendorf AS, Bojarski AJ. 5-HT1A receptor ligands and their therapeutic applications: review of new patents. Expert Opin Ther Pat. 2018;28(9):679–89.
Wesolowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol. 2007;18(5–6):439–46.
Ivachtchenko A V, Lavrovsky Y, Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders. J Alzheimer’s Dis. 2016;53(2):583–620.
Freeman AM, Westphal JR, Norris Gt, Roggero BA, Webb PB, Freeman KL, et al. Efficacy of ondansetron in the treatment of generalized anxiety disorder. Depress Anxiety. 1997;5(3).
Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon B, Marshall R, et al. Ondansetron in the treatment of panic disorder. Anxiety. 1996;2(4):199–202.
MacIsaac SE, Carvalho AF, Cha DS, Mansur RB, McIntyre RS. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother. 2014;15(2):259–74.
Weston NM, Gibbs D, Bird CI V, Daniel A, Jelen LA, Knight G, et al. Historic psychedelic drug trials and the treatment of anxiety disorders. Depress Anxiety. 2020;37(12):1261–79.
Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front psychiatry. 2020;10:494327.
Bergink V, Westenberg HGM. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol. 2005;20(6):291–3.
Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008;33(7):1603–10.
Kent JM, Daly E, Kezic I, Lane R, Lim P, De Smedt H, et al. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuro-Psychopharmacology Biol Psychiatry. 2016;67:66–73.
Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu D V, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2014;76(3):10121.
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, et al. Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325–33.
Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005;162(12):2379–81.
Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369–75.
Ori R, Amos T, Bergman H, Soares‐Weiser K, Ipser JC, Stein DJ. Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders. Cochrane Database Syst Rev. 2015;(5).
Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42(1):81–93.
Jevtović-Todorović V, Todorovć SM, Mennerick S, Powell S, Dikranian K, Benshoff N, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460–3.
Simen A, Whitlock M, Qiu R, Miceli J, Zumpano L, Du Metz M, et al. An 8-week, randomized, phase 2, double-blind, sequential parallel-group comparison study of two dose levels of the GABAA positive allosteric modulator PF-06372865 compared with placebo as an adjunctive treatment in outpatients with inadequate response to standard of care for generalized anxiety disorder. J Clin Psychopharmacol. 2019;39(1):20–7.
Wise T, Patrick F, Meyer N, Mazibuko N, Oates AE, van der Bijl AHM, et al. Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder. Biol Psychiatry. 2020;87(10):908–15.
Hoffmann E, Nomikos GG, Kaul I, Raines S, Wald J, Bullock A, et al. SAGE-217, a novel GABA A receptor positive allosteric modulator: Clinical pharmacology and tolerability in randomized phase I dose-finding studies. Clin Pharmacokinet. 2020;59:111–20.
Hecking J, Davoudian PA, Wilkinson ST. Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress. 2021;5:24705470211020450.
Acheson DT, Feifel D, Kamenski M, Mckinney R, Risbrough VB. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depress Anxiety. 2015;32(6):400–7.
Fang A, Treadway MT, Hofmann SG. Working hard for oneself or others: Effects of oxytocin on reward motivation in social anxiety disorder. Biol Psychol. 2017;127:157–62.
Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010;20(2):80–7.
Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, et al. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2013;16(1):1–11.
Reichmann F, Holzer P. Neuropeptide Y: A stressful review. Neuropeptides. 2016;55:99–109.
Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, et al. A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. Int J Neuropsychopharmacol. 2018;21(1):3–11.
Fabio KM, Guillon CD, Lu SF, Heindel ND, Brownstein MJ, Lacey CJ, et al. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013;102(6):2033–43.
Griebel G, Beeské S, Stahl SM. The Vasopressin V1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From 4 Randomized, Double-Blind, Placebo-Controlled Studiese. J Clin Psychiatry. 2012;73(11):1403.
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, et al. Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010;27(5):417–25.
Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull. 2020;36(4):432–48.
Lenze EJ, Hershey T, Newcomer JW, Karp JF, Blumberger D, Anger J, et al. Antiglucocorticoid therapy for older adults with anxiety and co‐occurring cognitive dysfunction: results from a pilot study with mifepristone. Int J Geriatr Psychiatry. 2014;29(9):962–9.
Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L. Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. Am J Psychiatry. 2014;171(6):675–82.
Liebowitz MR, Hanover R, Draine A, Lemming R, Careri J, Monti L. Effect of as‐needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depress Anxiety. 2016;33(12):1081–9.
Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006–17.
Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:476036.
GLASS RM, Uhlenhuth EH, HARTEL FW, SCHUSTER CR, FISCHMAN MW. Single‐dose study of nabilone in anxious volunteers. J Clin Pharmacol. 1981;21(S1):383S-396S.
Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 2002;16:731–43.
Ooi SL, Henderson P, Pak SC. Kava for generalized anxiety disorder: a review of current evidence. J Altern Complement Med. 2018;24(8):770–80.
Romero-Cerecero O, Islas-Garduño AL, Zamilpa A, Herrera-Arellano A, Jiménez-Ferrer E, Tortoriello J. Galphimine-B standardized extract versus alprazolam in patients with generalized anxiety disorder: a ten-week, double-blind, randomized clinical trial. Biomed Res Int. 2019;2019.
Hieu TH, Dibas M, Surya Dila KA, Sherif NA, Hashmi MU, Mahmoud M, et al. Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta‐analysis of randomized trials and quasi‐randomized trials. Phyther Res. 2019;33(6):1604–15.
Sarris J, McIntyre E. Herbal anxiolytics with sedative actions. Evidence-based Herb Nutr Treat anxiety Psychiatr Disord. 2017;11–31.
Marx W, Lane M, Rocks T, Ruusunen A, Loughman A, Lopresti A, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutr Rev. 2019;77(8):557–71.
Liu L, Liu C, Wang Y, Wang P, Li Y, Li B. Herbal medicine for anxiety, depression and insomnia. Curr Neuropharmacol. 2015;13(4):481–93.
Klemow KM, Bilbow E, Grasso D, Jones K, McDermott J, Pape E. Medical attributes of St. John’s wort (Hypericum perforatum). OXIDATIVE Stress Dis. 2004;14:757–80.
Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186.
Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K. Passiflora incarnata in neuropsychiatric disorders—A systematic review. Nutrients. 2020;12(12):3894.
Koulivand PH, Khaleghi Ghadiri M, Gorji A. Lavender and the nervous system. Evidence-based Complement Altern Med. 2013;2013.
Tammadon MR, Nobahar M, Hydarinia-Naieni Z, Ebrahimian A, Ghorbani R, Vafaei AA. The effects of valerian on sleep quality, depression, and state anxiety in hemodialysis patients: a randomized, double-blind, crossover clinical trial. Oman Med J. 2021;36(2):e255.
Ivanova Stojcheva E, Quintela JC. The effectiveness of Rhodiola rosea L. preparations in alleviating various aspects of life-stress symptoms and stress-induced conditions—encouraging clinical evidence. Molecules. 2022;27(12):3902.
Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with a bright future. Mol Med Rep. 2010;3(6):895–901.
Scholey A, Gibbs A, Neale C, Perry N, Ossoukhova A, Bilog V, et al. Anti-stress effects of lemon balm-containing foods. Nutrients. 2014;6(11):4805–21.
Bian T, Corral P, Wang Y, Botello J, Kingston R, Daniels T, et al. Kava as a clinical nutrient: promises and challenges. Nutrients. 2020;12(10):3044.
Cohen MM. Tulsi-Ocimum sanctum: A herb for all reasons. J Ayurveda Integr Med. 2014;5(4):251.
Khan I, Karim N, Ahmad W, Abdelhalim A, Chebib M. GABA-A receptor modulation and anticonvulsant, anxiolytic, and antidepressant activities of constituents from Artemisia indica Linn. Evidence-Based Complement Altern Med. 2016;2016.
Arozal W, Louisa M, Soetikno V. Selected Indonesian medicinal plants for the management of metabolic syndrome: Molecular basis and recent studies. Front Cardiovasc Med. 2020;7:82.
Petrovska BB. Historical review of medicinal plants’ usage. Pharmacogn Rev. 2012;6(11):1.
Chaachouay N, Zidane L. Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs Drug Candidates. 2024;3(1):184–207.
Hossain MF, Islam MA, Akhtar S, Numan SM. Nutritional value and medicinal uses of Monkey Jack fruit (Artocarpus lakoocha). Int Res J Biol Sci. 2016;5(1):60–3.
Sritularak B, Tantrakarnsakul K, Lipipun V, Likhitwitayawuid K. Flavonoids with anti-HSV activity from the root bark of Artocarpus lakoocha. Nat Prod Commun. 2013;8(8):1934578X1300800811.
Kumar MBS, Kumar MCR, Bharath AC, Kumar HRV, Kekuda TRP, Nandini KC, et al. Screening of selected biological activities of Artocarpus lakoocha Roxb (Moraceae) fruit pericarp. J basic Clin Pharm. 2010;1(4):239.
Krishnan K, Mathew LE, Vijayalakshmi NR, Helen A. Anti-inflammatory potential of β-amyrin, a triterpenoid isolated from Costus igneus. Inflammopharmacology. 2014;22:373–85.
Han N, Bakovic M. Biologically active triterpenoids and their cardioprotective and anti-inflammatory effects. J Bioanal Biomed S. 2015;12(005):1945–8.
Chuanasa T, Phromjai J, Lipipun V, Likhitwitayawuid K, Suzuki M, Pramyothin P, et al. Anti-herpes simplex virus (HSV-1) activity of oxyresveratrol derived from Thai medicinal plant: mechanism of action and therapeutic efficacy on cutaneous HSV-1 infection in mice. Antiviral Res. 2008;80(1):62–70.
Puntumchai A, Kittakoop P, Rajviroongit S, Vimuttipong S, Likhitwitayawuid K, Thebtaranonth Y. Lakoochins A and B, New Antimycobacterial Stilbene Derivatives from Artocarpus l akoocha. J Nat Prod. 2004;67(3):485–6.
Ko HH, Tsai YT, Yen MH, Lin CC, Liang CJ, Yang TH, et al. Norartocarpetin from a folk medicine Artocarpus communis plays a melanogenesis inhibitor without cytotoxicity in B16F10 cell and skin irritation in mice. BMC Complement Altern Med. 2013;13:1–12.
Tsai MH, Liu JF, Chiang YC, Hu SCS, Hsu LF, Lin YC, et al. Artocarpin, an isoprenyl flavonoid, induces p53-dependent or independent apoptosis via ROS-mediated MAPKs and Akt activation in non-small cell lung cancer cells. Oncotarget. 2017;8(17):28342.
Sritularak B, Tantrakarnsakul K, Likhitwitayawuid K, Lipipun V. New 2-arylbenzofurans from the root bark of Artocarpus lakoocha. Molecules. 2010;15(9):6548–58.
Sikarwar MS, Hui BJ, Subramaniam K, Valeisamy BD, Yean LK, Balaji K. A review on Artocarpus altilis (Parkinson) Fosberg (breadfruit). J Appl Pharm Sci. 2014;4(8):91–7.
Bhattacharya E, Dutta R, Chakraborty S, Biswas SM. Phytochemical profiling of Artocarpus lakoocha Roxb. leaf methanol extract and its antioxidant, antimicrobial and antioxidative activities. Asian Pac J Trop Biomed. 2019;9(11):484–92.
Li W, Zhou J, Xu Y. Study of the in vitro cytotoxicity testing of medical devices. Biomed reports. 2015;3(5):617–20.
Sitorus P, Keliat JM, Asfianti V, Muhammad M, Satria D. A literature review of Artocarpus lacucha focusing on the phytochemical constituents and pharmacological properties of the plant. Molecules. 2022;27(20):6940.
Alkhudhayri DA, Osman MA, Alshammari GM, Al Maiman SA, Yahya MA. Moringa peregrina leaf extracts produce anti-obesity, hypoglycemic, anti-hyperlipidemic, and hepatoprotective effects on high-fat diet fed rats. Saudi J Biol Sci. 2021;28(6):3333–42.
Tallima H, El Ridi R. Arachidonic acid: physiological roles and potential health benefits–a review. J Adv Res. 2018;11:33–41.
Milani DAQ, Davis DD. Pain management medications. In: StatPearls [Internet]. StatPearls Publishing; 2023.
Tadesse WT, Hailu AE, Gurmu AE, Mechesso AF. Experimental assessment of antidiarrheal and antisecretory activity of 80% methanolic leaf extract of Zehneria scabra in mice. BMC Complement Altern Med. 2014;14:1–8.
Nemeth V, Pfleghaar N. Diarrhea.[Updated 2021 Nov 29]. StatPearls [Internet] Treasure Isl StatPearls Publ. 2022;
Mahamud N, Songvut P, Muangnoi C, Rodsiri R, Dahlan W, Tansawat R. Untargeted metabolomics reveal pathways associated with neuroprotective effect of oxyresveratrol in SH-SY5Y cells. Sci Rep. 2023;13(1):20385.
Ashok A, Andrabi SS, Mansoor S, Kuang Y, Kwon BK, Labhasetwar V. Antioxidant therapy in oxidative stress-induced neurodegenerative diseases: Role of nanoparticle-based drug delivery systems in clinical translation. Antioxidants. 2022;11(2):408.
Nesa ML, Munira S, Bristy AS, Islam MM, Chayan H. Cytotoxic, anti-inflammatory, analgesic, CNS depressant, antidiarrhoeal activities of the methanolic extract of the Artocarpus Lakoocha leaves. World J Pharm Sci. 2015;167–74.
Saleem M, Asif A, Akhtar MF, Saleem A. Hepatoprotective potential and chemical characterization of Artocarpus lakoocha fruit extract. ||| Bangladesh J Pharmacol. 2018;13(1):90–7.
Raghavendra H, Mallikarjun N, Venugopal T, Anil Kumar HS. Elemental composition, anticariogenic, pancreatic lipase inhibitory and cytotoxic activity of Artocarpus lakoocha Roxb pericarp. Int J Drug Dev Res. 2012;4(1):330–6.
Preyavichyapugdee N, Sangfuang M, Chaiyapum S, Sriburin S, Pootaeng-on Y, Chusongsang P, et al. Schistosomicidal activity of the crude extract of Artocarpus lakoocha. Southeast Asian J Trop Med Public Heal. 2016;47:1–15.
Islam S, Shajib MS, Rashid R Bin, Khan MF, Al-Mansur MA, Datta BK, et al. Antinociceptive activities of Artocarpus lacucha Buch-ham (Moraceae) and its isolated phenolic compound, catechin, in mice. BMC Complement Altern Med. 2019;19:1–13.
Seiki S, Frishman WH. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev. 2009;17(2):70–6.
Pandey S, Poonia A. Monkey Jackfruit (Artocarpus lakoocha Roxb.): The Lesser-Known Fruit. Indian Food Ind. 2021;6:38–45.
Duarte Galhardo de Albuquerque RD, Mahomoodally MF, Lobine D, Suroowan S, Rengasamy KRR. Botanical products in the treatment and control of schistosomiasis: Recent studies and distribution of active plant resources according to affected regions. Biology (Basel). 2020;9(8):223.
Shohan FM, Baroi JA, Bhowmik P, Rupak MAHB, Ullah MR, Siddiq MAB, et al. An Evaluation of Anti-Hyperlipidemic Activity of Rubus idaeus on High Fat Induced Rat Model with Safety Profile Analysis. Asian J Res Cardiovasc Dis. 2023;5(1):163–70.
Crichton GE, Alkerwi A. Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. Lipids Health Dis. 2015;14:1–9.
Wongon M, Limpeanchob N. Inhibitory effect of Artocarpus lakoocha Roxb and oxyresveratrol on α-glucosidase and sugar digestion in Caco-2 cells. Heliyon. 2020;6(3).
Tripathi K, Kumar P, Kumar R, Saxena R, Kumar A, Badoni H, et al. Efficacy of jackfruit components in prevention and control of human disease: A scoping review. J Educ Health Promot. 2023;12(1):361.
Oli B Sen, Rauniyar A, Chad D. A review on the significance of the medicinal plant Acorus calamus. Asian J Pharmacogn. 2021;5(3):30–8.
Nansereko S, Muyonga J, Byaruhanga YB. Influence of drying methods on jackfruit drying behavior and dried products physical characteristics. Int J Food Sci. 2022;2022.
Sairam S, Urooj A. Safety evaluation of Artocarpus altilis as pharmaceutical agent in wistar rats. J Toxicol. 2014;2014.
Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World psychiatry. 2010;9(3):155.
Wainwright SR, Galea LAM. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast. 2013;2013.
Baliyan S, Mukherjee R, Priyadarshini A, Vibhuti A, Gupta A, Pandey RP, et al. Determination of antioxidants by DPPH radical scavenging activity and quantitative phytochemical analysis of Ficus religiosa. Molecules. 2022;27(4):1326.
Young SN. How to increase serotonin in the human brain without drugs. J psychiatry Neurosci JPN. 2007;32(6):394.
Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol. 2006;4(4):277–91.
Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán Mejía G. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev. 2016;2016.
Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35(1):4–26.
Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010;68(5):815–34.
Danhauer SC, Legault C, Bandos H, Kidwell K, Costantino J, Vaughan L, et al. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Aging, Neuropsychol Cogn. 2013;20(5):532–52.
Remes O, Mendes JF, Templeton P. Biological, psychological, and social determinants of depression: a review of recent literature. Brain Sci. 2021;11(12):1633.
Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;369–88.
Frank D, Gruenbaum BF, Zlotnik A, Semyonov M, Frenkel A, Boyko M. Pathophysiology and current drug treatments for post-stroke depression: a review. Int J Mol Sci. 2022;23(23):15114.
Steimer T. The biology of fear-and anxiety-related behaviors. Dialogues Clin Neurosci. 2002;4(3):231–49.
Yeo XY, Cunliffe G, Ho RC, Lee SS, Jung S. Potentials of neuropeptides as therapeutic agents for neurological diseases. Biomedicines. 2022;10(2):343.
Jewett BE, Sharma S. Physiology, GABA. 2018;
Tremblay R, Lee S, Rudy B. GABAergic interneurons in the neocortex: from cellular properties to circuits. Neuron. 2016;91(2):260–92.
Shaye H, Stauch B, Gati C, Cherezov V. Molecular mechanisms of metabotropic GABAB receptor function. Sci Adv. 2021;7(22):eabg3362.
Bryson A, Reid C, Petrou S. Fundamental neurochemistry review: GABAA receptor neurotransmission and epilepsy: principles, disease mechanisms and pharmacotherapy. J Neurochem. 2023;165(1):6–28.
